Product Reports Resources Pricing Login Book a demo

Hybio Pharmaceutical

Biotech & Life Sciences · Shenzhen, China · Founded 1998 · IPO 2011

Hybio Pharmaceutical Co., Ltd. is a high-tech enterprise focused on the research, development, and manufacturing of a wide range of peptide products. Established in 1998, Hybio has grown to become one of the largest and most professional peptide pharmaceutical companies in China. The company operates in the pharmaceutical industry, specifically targeting the peptide sector, which involves short chains of amino acids used in various medical treatments. Hybio serves a diverse clientele, including hospitals, research institutions, and pharmaceutical companies, both domestically and internationally. Hybio's business model revolves around the production and sale of peptide finished dosage products, peptide active pharmaceutical ingredients (APIs), and providing contract research and manufacturing services (CRO/CMO). The company generates revenue through the direct sale of its peptide products and by offering specialized services to other pharmaceutical companies. Hybio's market presence is bolstered by its comprehensive product range and its commitment to innovation and quality. The company has received numerous accolades, including being listed in Forbes China and winning the Shield Award. Hybio's participation in global events such as the AAPS Annual Meeting and CPHI Worldwide further underscores its prominence in the industry. Keywords: peptide, pharmaceutical, R&D, manufacturing, APIs, CRO, CMO, China, innovation, quality.

Valuation $2.5–5B
Revenue $100–500M
EBITDA $46M
Headcount <100
Total funding $0–10M

Investors

2 investors on Hybio Pharmaceutical's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 2 investors entered at this stage

Global footprint

Where Hybio Pharmaceutical has talent and traffic

Workforce by country
1 countries with
team presence
🇨🇳 China100%
1 country shown
Web traffic by country
570 monthly visits
across markets
🇺🇸 United States105.3%
Top 1 markets shown

Talent graph

The shape of Hybio Pharmaceutical's talent

Dealroom maps Hybio Pharmaceutical's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

1 team members profilednamed & role-tagged by Dealroom
57 employeestotal headcount
DimensionScore
AI Talent Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Hybio Pharmaceutical's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Market sentiment

What the market is saying about Hybio Pharmaceutical

An AI-synthesized read of the highest-engagement posts about Hybio Pharmaceutical on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Hybio Pharmaceutical on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.